Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment.

Abstract

The diagnosis of early and aggressive types of cancer is important for providing effective cancer therapy. Cancer-induced fibrin clots exist only within lesions. Previously, we developed a monoclonal antibody (clone 102-10) that recognizes insoluble fibrin but not fibrinogen or soluble fibrin and confirmed that fibrin clots form continuously in various cancers. Here, we describe the development of a Fab fragment probe of clone 102-10 for tumour imaging. The distribution of 102-10 Fab was investigated in genetically engineered mice bearing pancreatic ductal adenocarcinoma (PDAC), and its effect on blood coagulation was examined. Immunohistochemical and ex vivo imaging revealed that 102-10 Fab was distributed selectively in fibrin clots in PDAC tumours 3 h after injection and that it disappeared from the body after 24 h. 102-10 Fab had no influence on blood coagulation or fibrinolysis. Tumour imaging using anti-fibrin Fab may provide a safe and effective method for the diagnosis of invasive cancers by detecting fibrin clots in tumour stroma.

• Authors: Toshifumi Obonai, Hirobumi Fuchigami, Fumiaki Furuya, Naoyuki Kozuka, Masahiro Yasunaga, Yasuhiro Matsumura
• Journal: Scientific reports (Sci Rep) Vol. 6 Pg. 23613 (Mar 24 2016) ISSN: 2045-2322 [Electronic] England
• PMID: 27009516 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Fibrin

Topics

• Animals
• Antibodies, Monoclonal (administration & dosage, pharmacology)
• Carcinoma, Pancreatic Ductal (diagnosis, genetics, metabolism)
• Early Detection of Cancer
• Fibrin (immunology)
• Genetic Engineering
• Humans
• Mice
• Mutation
• Neoplasms, Experimental
• Pancreatic Neoplasms (genetics, metabolism)
• Tumor Microenvironment